Compare Citius Pharmaceuticals Inc (CTXR) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Altria Group Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Altria Group Inc trades at $70.3 (market cap $117.16B). The key difference: Altria Group Inc is far larger — about 8002.7× Citius Pharmaceuticals Inc's market cap, and Altria Group Inc pays a 6.04% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MO | |
|---|---|---|
Market Cap | $14.64M | $117.16B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $74.55 |
52-Week Low | $0.53 | $54.72 |
Enterprise Value | $10.86M | $138.23B |
Dividend Yield | — | 6.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
MO trades at $71.87, up 0.14% today, with a neutral technical signal and bullish moving averages. The company reported a net income margin of 39.52% for 2025, with recent earnings beating expectations in Q1 2026. Strong cash flow from operations of $9.29B supports its dividend, with a recent $1.06 payment declared. Analyst consensus is bullish with a $71.00 price target.
Outlook remains stable with defensive qualities highlighted by media, but risks include high debt levels and regulatory pressures. The stock offers a high yield and pricing power, though revenue trends show slight volatility. Investment appeal centers on dividend sustainability and cash flow generation amid a challenging industry backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
